Report cover image

Transdermal Drug Delivery Systems Market By Type Of Delivery System (Passive, Active), By Application (Analgesics, Hormone Replacement Therapies, Hypertension, Motion Sickness, Smoking Cessation, Others): Global Opportunity Analysis and Industry Forecast,

Publisher Allied Market Research
Published Mar 01, 2022
Length 175 Pages
SKU # ALMR17334402

Description

Transdermal Drug Delivery Systems Market By Type Of Delivery System (Passive, Active), By Application (Analgesics, Hormone Replacement Therapies, Hypertension, Motion Sickness, Smoking Cessation, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030

The global transdermal drug delivery systems market size was valued at $52,476.5 million in 2020, and is projected to reach $87,322.4 million by 2030, registering a CAGR of 4.9% from 2021 to 2030. Transdermal drug delivery systems are dosage forms that are designed to deliver an effective amount of drug across a patient's skin. The adhesive used in transdermal drug delivery systems govern the safety, efficiency, and quality of the product.

Transdermal drug delivery systems are capable of maintaining adequate concentration of medicine in the blood for a long period of time. These systems can also reduce the chances of systemic adverse reactions, such as gastrointestinal tract disorders.

The increase in number of patients suffering from chronic diseases, such as heart diseases, diabetes, and arthritis has significantly increased owing to lifestyle changes and stressful work culture. Furthermore, the global geriatric population is also on the rise. These factors positively influence the growth of the market. However, side-effects caused by the use of transdermal drug delivery systems can restraint the market growth. Advancements in technologies enable the use of transdermal systems for delivering a wide range of drugs.

The transdermal drug delivery systems market is segmented on the basis of type of delivery, application, and region. By type of delivery, the market is classified into passive and active.. By application, it is categorized into analgesics, hormone replacement therapy, hypertension, motion sickness, smoking cessation and others . By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major players operating in the global market have adopted key strategies such as product launch to strengthen their market outreach and sustain the stiff competition in the market

COMPETITION ANALYSIS

The major market participants profiled in this report include Altaris, Bayer AG, Boehringer Ingelheim GmbH, Endo International plc, GlaxoSmithKline plc, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson, Novartis AG, Purdue Pharma L.P. and Viatris Inc.

KEY BENEFITS FOR STAKEHOLDERS

The report provides an extensive analysis of the current and emerging transdermal drug delivery systems market trends and dynamics.
In-depth market analysis is conducted by constructing market estimations for the key market segments between 2020 and 2030.
Extensive analysis of the transdermal drug delivery systems market is conducted by following key product positioning and monitoring of the top competitors within the market framework.
A comprehensive analysis of all regions is provided to determine the prevailing opportunities.
The global transdermal drug delivery systems market forecast analysis from 2021 to 2030 is included in the report.
The key market players within transdermal drug delivery systems market are profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the transdermal drug delivery systems industry.

Key Market Segments

By BY TYPE OF DELIVERY SYSTEM

Passive
Active

By BY APPLICATION

Analgesics
Hormone Replacement Therapies
Hypertension
Motion Sickness
Smoking Cessation
Others

By BY REGION

Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
North America
U.S
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe

Key Market Players

Viatris Inc.
Bayer AG
Boehringer Ingelheim GmbH
Endo International plc
GlaxoSmithKline plc
Johnson & Johnson
Novartis AG
Purdue Pharma L.P.
Altaris
Hisamitsu Pharmaceutical Co. Inc.

Table of Contents

175 Pages
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM
4.1 Overview
4.1.1 Market size and forecast
4.2 Passive
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Active
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Analgesics
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Hormone Replacement Therapies
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Hypertension
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Motion Sickness
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Smoking Cessation
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
5.7 Others
5.7.1 Key market trends, growth factors and opportunities
5.7.2 Market size and forecast, by region
5.7.3 Market analysis by country
CHAPTER 6: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 Asia-Pacific
6.2.1 Key trends and opportunities
6.2.2 Asia-Pacific Market size and forecast, by Type Of Delivery System
6.2.3 Asia-Pacific Market size and forecast, by Application
6.2.4 Asia-Pacific Market size and forecast, by country
6.2.4.1 Japan
6.2.4.1.1 Market size and forecast, by Type Of Delivery System
6.2.4.1.2 Market size and forecast, by Application
6.2.4.2 China
6.2.4.2.1 Market size and forecast, by Type Of Delivery System
6.2.4.2.2 Market size and forecast, by Application
6.2.4.3 India
6.2.4.3.1 Market size and forecast, by Type Of Delivery System
6.2.4.3.2 Market size and forecast, by Application
6.2.4.4 Australia
6.2.4.4.1 Market size and forecast, by Type Of Delivery System
6.2.4.4.2 Market size and forecast, by Application
6.2.4.5 South Korea
6.2.4.5.1 Market size and forecast, by Type Of Delivery System
6.2.4.5.2 Market size and forecast, by Application
6.2.4.6 Rest of Asia-Pacific
6.2.4.6.1 Market size and forecast, by Type Of Delivery System
6.2.4.6.2 Market size and forecast, by Application
6.3 LAMEA
6.3.1 Key trends and opportunities
6.3.2 LAMEA Market size and forecast, by Type Of Delivery System
6.3.3 LAMEA Market size and forecast, by Application
6.3.4 LAMEA Market size and forecast, by country
6.3.4.1 Brazil
6.3.4.1.1 Market size and forecast, by Type Of Delivery System
6.3.4.1.2 Market size and forecast, by Application
6.3.4.2 Saudi Arabia
6.3.4.2.1 Market size and forecast, by Type Of Delivery System
6.3.4.2.2 Market size and forecast, by Application
6.3.4.3 South Africa
6.3.4.3.1 Market size and forecast, by Type Of Delivery System
6.3.4.3.2 Market size and forecast, by Application
6.3.4.4 Rest of LAMEA
6.3.4.4.1 Market size and forecast, by Type Of Delivery System
6.3.4.4.2 Market size and forecast, by Application
6.4 North America
6.4.1 Key trends and opportunities
6.4.2 North America Market size and forecast, by Type Of Delivery System
6.4.3 North America Market size and forecast, by Application
6.4.4 North America Market size and forecast, by country
6.4.4.1 U.S.
6.4.4.1.1 Market size and forecast, by Type Of Delivery System
6.4.4.1.2 Market size and forecast, by Application
6.4.4.2 Canada
6.4.4.2.1 Market size and forecast, by Type Of Delivery System
6.4.4.2.2 Market size and forecast, by Application
6.4.4.3 Mexico
6.4.4.3.1 Market size and forecast, by Type Of Delivery System
6.4.4.3.2 Market size and forecast, by Application
6.5 Europe
6.5.1 Key trends and opportunities
6.5.2 Europe Market size and forecast, by Type Of Delivery System
6.5.3 Europe Market size and forecast, by Application
6.5.4 Europe Market size and forecast, by country
6.5.4.1 Germany
6.5.4.1.1 Market size and forecast, by Type Of Delivery System
6.5.4.1.2 Market size and forecast, by Application
6.5.4.2 France
6.5.4.2.1 Market size and forecast, by Type Of Delivery System
6.5.4.2.2 Market size and forecast, by Application
6.5.4.3 U.K.
6.5.4.3.1 Market size and forecast, by Type Of Delivery System
6.5.4.3.2 Market size and forecast, by Application
6.5.4.4 Italy
6.5.4.4.1 Market size and forecast, by Type Of Delivery System
6.5.4.4.2 Market size and forecast, by Application
6.5.4.5 Spain
6.5.4.5.1 Market size and forecast, by Type Of Delivery System
6.5.4.5.2 Market size and forecast, by Application
6.5.4.6 Rest of Europe
6.5.4.6.1 Market size and forecast, by Type Of Delivery System
6.5.4.6.2 Market size and forecast, by Application
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Viatris Inc.
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Bayer AG
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 Boehringer Ingelheim GmbH
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Endo International plc
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 GlaxoSmithKline plc
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Johnson & Johnson
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 Novartis AG
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Purdue Pharma L.P.
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 Altaris
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Hisamitsu Pharmaceutical Co. Inc.
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM, 2020-2030,($MILLION)
TABLE 2. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR PASSIVE, BY REGION , 2020-2030,($MILLION)
TABLE 3. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET PASSIVE BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR ACTIVE, BY REGION , 2020-2030,($MILLION)
TABLE 5. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET ACTIVE BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 7. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR ANALGESICS, BY REGION , 2020-2030,($MILLION)
TABLE 8. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET ANALGESICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 9. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR HORMONE REPLACEMENT THERAPIES, BY REGION , 2020-2030,($MILLION)
TABLE 10. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET HORMONE REPLACEMENT THERAPIES BY COUNTRY, 2020-2030,($MILLION)
TABLE 11. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR HYPERTENSION, BY REGION , 2020-2030,($MILLION)
TABLE 12. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET HYPERTENSION BY COUNTRY, 2020-2030,($MILLION)
TABLE 13. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR MOTION SICKNESS, BY REGION , 2020-2030,($MILLION)
TABLE 14. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET MOTION SICKNESS BY COUNTRY, 2020-2030,($MILLION)
TABLE 15. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR SMOKING CESSATION, BY REGION , 2020-2030,($MILLION)
TABLE 16. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SMOKING CESSATION BY COUNTRY, 2020-2030,($MILLION)
TABLE 17. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
TABLE 18. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 19. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 20. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM, 2020-2030,($MILLION)
TABLE 21. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 22. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 23. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 24. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 25. CHINA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 26. CHINA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 27. INDIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 28. INDIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 29. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 30. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 31. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 32. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 33. REST OF ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 34. REST OF ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 35. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM, 2020-2030,($MILLION)
TABLE 36. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 37. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 38. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 39. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 40. SAUDI ARABIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 41. SAUDI ARABIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 42. SOUTH AFRICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 43. SOUTH AFRICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 44. REST OF LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 45. REST OF LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 46. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM, 2020-2030,($MILLION)
TABLE 47. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 48. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 49. U.S. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 50. U.S. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 51. CANADA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 52. CANADA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 53. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 54. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 55. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM, 2020-2030,($MILLION)
TABLE 56. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 57. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 58. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 59. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 60. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 61. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 62. U.K. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 63. U.K. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 64. ITALY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 65. ITALY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 66. SPAIN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 67. SPAIN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 68. REST OF EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 69. REST OF EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 70.VIATRIS INC.: COMPANY SNAPSHOT
TABLE 71.VIATRIS INC.: OPERATING SEGMENTS
TABLE 72.VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 73.VIATRIS INC.: NET SALES,
TABLE 74.VIATRIS INC.: KEY STRATERGIES
TABLE 75.BAYER AG: COMPANY SNAPSHOT
TABLE 76.BAYER AG: OPERATING SEGMENTS
TABLE 77.BAYER AG: PRODUCT PORTFOLIO
TABLE 78.BAYER AG: NET SALES,
TABLE 79.BAYER AG: KEY STRATERGIES
TABLE 80.BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
TABLE 81.BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
TABLE 82.BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
TABLE 83.BOEHRINGER INGELHEIM GMBH: NET SALES,
TABLE 84.BOEHRINGER INGELHEIM GMBH: KEY STRATERGIES
TABLE 85.ENDO INTERNATIONAL PLC: COMPANY SNAPSHOT
TABLE 86.ENDO INTERNATIONAL PLC: OPERATING SEGMENTS
TABLE 87.ENDO INTERNATIONAL PLC: PRODUCT PORTFOLIO
TABLE 88.ENDO INTERNATIONAL PLC: NET SALES,
TABLE 89.ENDO INTERNATIONAL PLC: KEY STRATERGIES
TABLE 90.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 91.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 92.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 93.GLAXOSMITHKLINE PLC: NET SALES,
TABLE 94.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 95.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 96.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 97.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 98.JOHNSON & JOHNSON: NET SALES,
TABLE 99.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 100.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 101.NOVARTIS AG: OPERATING SEGMENTS
TABLE 102.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 103.NOVARTIS AG: NET SALES,
TABLE 104.NOVARTIS AG: KEY STRATERGIES
TABLE 105.PURDUE PHARMA L.P.: COMPANY SNAPSHOT
TABLE 106.PURDUE PHARMA L.P.: OPERATING SEGMENTS
TABLE 107.PURDUE PHARMA L.P.: PRODUCT PORTFOLIO
TABLE 108.PURDUE PHARMA L.P.: NET SALES,
TABLE 109.PURDUE PHARMA L.P.: KEY STRATERGIES
TABLE 110.ALTARIS: COMPANY SNAPSHOT
TABLE 111.ALTARIS: OPERATING SEGMENTS
TABLE 112.ALTARIS: PRODUCT PORTFOLIO
TABLE 113.ALTARIS: NET SALES,
TABLE 114.ALTARIS: KEY STRATERGIES
TABLE 115.HISAMITSU PHARMACEUTICAL CO. INC.: COMPANY SNAPSHOT
TABLE 116.HISAMITSU PHARMACEUTICAL CO. INC.: OPERATING SEGMENTS
TABLE 117.HISAMITSU PHARMACEUTICAL CO. INC.: PRODUCT PORTFOLIO
TABLE 118.HISAMITSU PHARMACEUTICAL CO. INC.: NET SALES,
TABLE 119.HISAMITSU PHARMACEUTICAL CO. INC.: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION
FIGURE 2.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030
FIGURE 3.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,BY TYPE OF DELIVERY SYSTEM,2020(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF PASSIVE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ACTIVE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 14.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,BY APPLICATION,2020(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ANALGESICS TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HORMONE REPLACEMENT THERAPIES TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HYPERTENSION TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF SMOKING CESSATION TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 21.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY REGION,2020
FIGURE 22.JAPAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 23.CHINA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 24.INDIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 25.AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 26.SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 27.REST OF ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 28.BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 29.SAUDI ARABIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 30.SOUTH AFRICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 31.REST OF LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 32.U.S. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 33.CANADA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 34.MEXICO TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 35.GERMANY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 36.FRANCE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 37.U.K. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 38.ITALY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 39.SPAIN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 40.REST OF EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 45.COMPETITIVE DASHBOARD
FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 47.VIATRIS INC..: NET SALES ,($MILLION)
FIGURE 48.BAYER AG.: NET SALES ,($MILLION)
FIGURE 49.BOEHRINGER INGELHEIM GMBH.: NET SALES ,($MILLION)
FIGURE 50.ENDO INTERNATIONAL PLC.: NET SALES ,($MILLION)
FIGURE 51.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
FIGURE 52.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
FIGURE 53.NOVARTIS AG.: NET SALES ,($MILLION)
FIGURE 54.PURDUE PHARMA L.P..: NET SALES ,($MILLION)
FIGURE 55.ALTARIS.: NET SALES ,($MILLION)
FIGURE 56.HISAMITSU PHARMACEUTICAL CO. INC..: NET SALES ,($MILLION)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us